RxDoctor Payments DataLook up a doctor →

Jayant Kumar, MD

Nephrology · Albuquerque, NMNPI 1558451039

Payments from drug & device makers

$2,854,402in general payments, 2019–2025

Across 1,328 payments — averaging $2149.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$966K
  • AstraZeneca$917K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$265K
  • Astrazeneca UK Limited$233K
  • Vertex$137K
  • Novo Nordisk AS$111K
  • plus $225K from 36 others

What the payments were for

  • Consulting fees$2,40020%
  • Travel & lodging$1,61813%
  • Food & beverage$8,17667%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,854,402 in reported general payments places this provider in the 95th percentile of 68 nephrology providers in New Mexico.

See all nephrology providers in New Mexico

Medicare billing

Part B allowed, 2024
$340,905
Medicare patients
413
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide49$133,393
FarxigaDapagliflozin Propanediol41$31,795
Lanthanum Carbonate11$12,000
LokelmaSodium Zirconium Cyclosilicate16$10,578
JardianceEmpagliflozin13$9,970
Sevelamer Carbonate57$8,242
JanuviaSitagliptin Phosphate13$7,604
Valganciclovir Hcl77$6,594
VeltassaPatiromer Calcium Sorbitex12$5,964
Tacrolimus45$5,043
Mycophenolic AcidMycophenolate Sodium34$3,841
Amlodipine Besylate166$1,845
Famotidine180$1,844
Calcium Acetate13$1,780
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$3,762$133,39349 claims
AstraZenecaFarxiga, Lokelma$917,378$42,37457 claims
Boehringer IngelheimJardiance$152$9,97013 claims
MerckJanuvia$33,132$7,60413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 nephrology providers in New Mexico.

Other nephrology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →